Combating Illicit Xylazine Act
Latest action · Apr 15, 2026 Placed on Senate Legislative Calendar under General Orders. Calendar No. 372.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedFeb 12, 2025
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Combating Illicit Xylazine Act
This bill regulates xylazine under the Controlled Substances Act (CSA).
Xylazine, also known as tranq, is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine.
This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused.
Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA.
The bill exempts from registration under the CSA persons and entities that possess xylazine (1) lawfully dispensed by a veterinarian or pharmacy and (2) for an animal or for use in certain animal-control or wildlife programs.
The bill also exempts xylazine manufacturers from the CSA's physical security requirements.
Finally, the bill requires the DEA, in coordination with the Department of Health and Human Services (HHS), to provide Congress with a report on how the agencies previously determined whether xylazine should be a controlled substance, including the full text of HHS's recommendations to the DEA for scheduling xylazine.
Cosponsors 35
Members who signed on, in the order they did. Signatures ran from Feb 12, 2025 to Jun 9, 2026; 18 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-MN | Amy Klobuchar | Original | Feb 12, 2025 |
| D-NM | Ben Ray Luján | Original | Feb 12, 2025 |
| R-IA | Chuck Grassley | Original | Feb 12, 2025 |
| R-MS | Cindy Hyde-Smith | Original | Feb 12, 2025 |
| D-NV | Jacky Rosen | Original | Feb 12, 2025 |
| R-ID | James E. Risch | Original | Feb 12, 2025 |
| D-NH | Jeanne Shaheen | Original | Feb 12, 2025 |
| R-AL | Katie Boyd Britt | Original | Feb 12, 2025 |
| D-NY | Kirsten E. Gillibrand | Original | Feb 12, 2025 |
| D-NH | Margaret Wood Hassan | Original | Feb 12, 2025 |
| D-WA | Maria Cantwell | Original | Feb 12, 2025 |
| D-AZ | Mark Kelly | Original | Feb 12, 2025 |
| D-CT | Richard Blumenthal | Original | Feb 12, 2025 |
| R-FL | Rick Scott | Original | Feb 12, 2025 |
| R-MS | Roger F. Wicker | Original | Feb 12, 2025 |
| R-WV | Shelley Moore Capito | Original | Feb 12, 2025 |
| D-VA | Tim Kaine | Original | Feb 12, 2025 |
| R-IN | Todd Young | Original | Feb 12, 2025 |
| D-AZ | Ruben Gallego | Feb 18, 2025 | |
| R-NC | Thom Tillis | Feb 24, 2025 | |
| D-PA | John Fetterman | Jul 16, 2025 | |
| D-CO | Michael F. Bennet | Jul 22, 2025 | |
| R-WY | Cynthia M. Lummis | Jul 23, 2025 | |
| R-NC | Ted Budd | Jul 23, 2025 | |
| I-ME | Angus S. King Jr. | Jul 24, 2025 | |
| R-WV | James C. Justice | Sep 10, 2025 | |
| R-ID | Mike Crapo | Sep 29, 2025 | |
| R-PA | David McCormick | Feb 10, 2026 | |
| R-OK | James Lankford | Feb 24, 2026 | |
| R-FL | Ashley Moody | Mar 17, 2026 | |
| R-TX | John Cornyn | Mar 19, 2026 | |
| R-TN | Marsha Blackburn | Mar 19, 2026 | |
| D-IL | Richard J. Durbin | Mar 26, 2026 | |
| R-TX | Ted Cruz | Mar 26, 2026 | |
| D-OR | Jeff Merkley | Jun 9, 2026 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| Senate | Judiciary Committee | Referred Feb 12, 2025Markup Mar 26, 2026 |
Actions 5
Everything that happened, newest first.
- Apr 15, 2026Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
- Apr 15, 2026Placed on Senate Legislative Calendar under General Orders. Calendar No. 372.
- Mar 26, 2026Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Feb 12, 2025Introduced in Senate
- Feb 12, 2025Read twice and referred to the Committee on the Judiciary.
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 1266 | Combating Illicit Xylazine Act | Related bill | Sep 16, 2026 |
Titles 3
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- A bill to prohibit certain uses of xylazine, and for other purposes.
- Short Title(s) as Introduced
- Combating Illicit Xylazine Act
- Short Title(s) as Reported to Senate
- Combating Illicit Xylazine Act
Subjects
Assigned by the Library of Congress. Policy area: Crime and Law Enforcement.
- Congressional oversight
- Consumer affairs
- Crime and Law Enforcement
- Criminal procedure and sentencing
- Drug safety, medical device, and laboratory regulation
- Drug trafficking and controlled substances
- Licensing and registrations
- Manufacturing
- U.S. Sentencing Commission
- Veterinary medicine and animal diseases
Text 2
Each version as it was printed, newest first.
- Apr 15, 2026Reported to Senate
- Feb 12, 2025Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.